You have no items in your shopping cart.
Histone Methyltransferase
50 Item(s)
per page
| Catalog No. | Product Name | Application | Product Information |
|---|---|---|---|
A11757 SALE |
GSK126 |
EZH2 inhibitor |
GSK126 is a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes.
|
A15916 |
AMI-1 |
Hmt1p/PRMT1 Inhibitor |
AMI-1 is a potent and specific Histone Methyltransferase (HMT) inhibitor with IC50 of 3.0 uM and 8.8 uM for yeast Hmt1p and human PRMT1, respectively.
|
A15908 |
CPI-360 |
EZH1 inhibitor |
CPI-360 is a potent, selective,and SAM-competitive EZH1 inhibitor with IC50 of 102.3 nM, >100-fold selectivity over other methyltransferases.
|
A14374 SALE |
GSK591 |
PRMT5 inhibitor |
GSK591 is a potent selective inhibitor of the arginine methyltransferase PRMT5 with IC50 of 11 nM.
|
A13166 SALE |
UNC-1999 |
EZH2/EZH1 Inhibitor |
UNC1999 is the first orally bioavailable inhibitor that has high in vitro potency for wildtype and mutant EZH2 as well as EZH1.
|
A15549 |
GSK503 |
EZH2 Inhibitor |
GSK-503 is a potent EZH2 inhibitor with potential anticancer activity.
|
A12585 SALE |
MS023
|
PRMT1 inhibitor |
MS023 is a potent inihbitor of PRMTs 1,3,4,6,and 8 (IC50 = 30, 119, 83, 8, and 8 nM, respectively), which are responsible for asymmetric dimethylation of arginine residues.
|
A11377 |
DZNep |
EZH2 Inhibitor |
3 Deazaneplanocin A (DZNep) is a cyclopentenyl analog of 3-deazaadenosine, originally synthesized as an inhibitor of S-adenosyl-L-homocysteine hydrolase.
|
A15544 |
EPZ011989 |
EZH2 Inhibitor |
EPZ011989 is a potent, selective orally bioavailable EZH2 inhibitor with Ki < 3 nM for EZH2 wt and EZH2 Y646; 15-fold selectivity over EZH1 and >3000-fold selectivity over other HMTase.
|
A15920 SALE |
CPI-169 |
EZH2 inhibitor |
CPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.
|
A12929 |
MI-2 (Menin-MLL inhibitor 2) |
Menin-MLL interaction inhibitor |
MI-2 (Menin-MLL inhibitor 2) specifically binds to Menin and inhibits Menin??s interaction with MLL fusion proteins in cells. It can effectively reverse MLL fusion protein?Cmediated leukemic transformation by downregulating the expression of target genes downstream of MLL fusion protein oncogenic activity. MI-2 is a new tool for better understanding MLL-mediated leukemogenesis and represents a new approach for studying the role of Menin as an oncogenic cofactor of MLL fusion proteins.
|
A15450 SALE |
SGC 707 |
PRMT3 Inhibitor |
SGC 707 is a potent allosteric inhibitor of PRMT3 (IC50 = 50 nM) with >100-fold selectivity over other methyltransferases and other non-epigenetic targets.
|
A15813 SALE |
LLY-507 |
SMYD2 inhibitor |
LLY-507 is a cell-active, small molecule inhibitor of SMYD2 with IC50 of= 15 nM.
|
A15807 |
XY1 |
PRMT3 inhibitor |
XY1 is a negative control of SGC 707 . SGC 707 (Adooq Catalog# A15450) is a potent, selective allosteric inhibitor of PRMT3 (IC50 = 50 nM).
|
A15928 |
WDR5-0103 |
WDR5 antagonist |
WDR5-0103 is a small molecule that binds a peptide-binding pocket on WDR5 (Kd = 450 nM), inhibiting the catalytic activity of the MLL core complex in vitro (IC50 = 39 M).
|
A15870 |
HLCL-61 |
PRMT5 Inhibitor |
HLCL-61 hydrochloride is a potent and selective PRMT5 inhibitor for the treatment of acute myeloid leukemia.
|
A16378 |
TC-E 5003 |
PRMT1 inhibitor |
TC-E 5003 is a selective inhibitor of PRMT1 with IC50 value of 1.5 uM .
|
A16377 |
EPZ020411 |
PRMT6 inhibitor |
EPZ020411 is a potent and selective inhibitor of PRMT6 with IC50 of 10 nM, has >10 fold selectivity for PRMT6 over PRMT1 and PRMT8.
|
A16375 |
EPZ031686 |
SMYD3/ MEKK2 inhibitor |
EPZ031686 is a noncompetitive inhibitor for SMYD3 and MEKK2 with a Ki=1.2 and 1.1 nM respectively.
|
A16357 |
CPI-1205 |
EZH2 inhibitor |
CPI-1205 is a highly potent (biochemical IC50 = 0.002 μM, cellular EC50 = 0.032 μM) and selective inhibitor of EZH2.
|
A13169 |
AZ505 ditrifluoroacetate |
SMYD2 inhibitor |
AZ505 ditrifluoroacetate is a potent and highly selective inhibitor of the oncogenic protein SMYD2(IC50=0.12 uM) with potential anticancer activity, >600 fold than SMYD3(IC50>83.3 uM); DOT1L(IC50>83.3 uM);EZH2(IC50>83.3 uM).
|
A13061 |
AZ505 |
SMYD2 inhibitor |
AZ505 is a potent and highly selective inhibitor of the oncogenic protein SMYD2(IC50=0.12 μM) with potential anticancer activity, >600 fold than SMYD3(IC50>83.3 μM); DOT1L(IC50>83.3 μM);EZH2(IC50>83.3 μM).
|
A12711 |
EI1 |
EZH2 inhibitor |
EI1 is a potent and selective small molecule inhibitor of EZH2 with IC50 values of 15 nM and 13 nM for wild type EZH2 and EZH2 Y641F mutant, respectively.
|
A13282 |
UNC 2400 |
EZH1/EZH2 inhibitor |
UNC 2400, a close analogue of UNC1999, is a negative control of UNC1999 that inhibits EZH2 and EZH1.
|
A11599 |
UNC3866 |
CBX4 /CBX7 chromodomains antagonist |
UNC3866 is a potent antagonist of CBX4 and CBX7 chromodomains with a Kd of ~100 nM for each, and is 6- to 18-fold selective as compared to seven other CBX and CDY chromodomains.
|
A15969 SALE |
A-366 |
G9a/GLP inhibitor |
A-366 is a potent and selective G9a/GLP histone lysine methyltransferase inhibitor with IC50 value of 3.3 nM.
|
A12947 SALE |
UNC0638
|
G9a/GLP HMTase inhibitor |
UNC0638 is an inhibitor of protein lysine methyltransferases G9a(IC50<15 nM) and GLP(IC50=19 nM) with excellent potency and selectivity over a wide range of epigenetic and non-epigenetic targets.
|
A15487 SALE |
UNC0642 |
G9a/GLP inhibitor |
UNC0642 is a potent and selective G9a and GLP histone lysine methyltransferase inhibitor (IC50 < 2.5 nM). It reduces H3K9 dimethylation levels in MDA-MB-231 cells (IC50 = 110 nM). Displays modest brain penetration in vivo.
|
A12712 SALE |
EPZ-6438 (Tazemetostat) |
EZH2 inhibitor |
EPZ-6438 is a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity. It induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells.
|
A13200 |
UNC0321 |
G9a HMTase inhibitor |
UNC0321 is the first G9a inhibitor with picomolar potency and the most potent G9a inhibitor to date
|
A13110 |
Opicapone (BIA 9-1067) |
COMT inhibitor |
opicapone is a novel catechol-O-methyltransferase inhibitor
|
A13114 SALE |
GSK343 |
EZH2 inhibitor |
GSK343 is a potent histone H3-lysine 27 (H3K27) methyltransferase EZH2 inhibitor (IC= 4 nM). Diplays 1000-fold selectivity for other HMTs except EZH1 (60-fold selectivity). GSK343 inhibits H3K27 methylation in HCC1806 cells with an IC of <200nM (measured by immunofluorescence).
|
A13195 |
UNC0631 |
G9a inhibitor |
UNC-0631 is a novel G9a inhibitor with excellent potency in a variety of cell lines and excellent separation of functional potency versus cell toxicity.
|
A13194 SALE |
UNC0646 |
G9a/GLP HMTase inhibitor |
UNC0646 is a potent and selective inhibitor of the homologous protein lysine methyltransferases, G9a and GLP (IC50 values are 6 nM and 15 nM for G9a and GLP, respectively).
|
A12812 |
Chaetocin |
SUV39H HMT Inhibitor |
Chaetocin is a histone methyltransferase SUV39H1 inhibitor (IC50 = 0.8 μM). Induces apoptosis in myeloma cell lines in vitro; exhibits antiproliferative activity in a mouse myeloma model in vivo.
|
A12735 SALE |
EPZ-5676 (Pinometostat) |
DOT1L Inhibitor |
EPZ-5676 is a small molecule inhibitor of histone methyltransferase with potential antineoplastic activity.
|
A11763 SALE |
BIX 01294 |
G9a/GLP HMT inhibitor |
BIX 01294 is a G9a-like protein and G9a histone lysine methyltransferase inhibitor.
|
A12983 |
EPZ004777 |
DOT1L inhibitor |
EPZ004777 is a potent, selective inhibitor of DOT1L. EPZ004777 selectively inhibits cellular H3K79 methylation and inhibits expression of key MLL fusion target genes.
|
A12941 SALE |
SGC 0946 |
DOT1L inhibitor |
SGC 0946 is a potent DOT1L methyltransferase inhibitor that blocks H3K79 methylation in A431 cells and MCF10A cells.
|
A14315 |
MM-102 |
MLL1 inhibitor |
MM-102 is a high-affinity peptidomimetic MLL1 inhibitor with IC50 of 0.4 uM.
|
A15388 |
UNC 0224
|
G9a inhibitor |
UNC0224 is a potent and selective G9a inhibitor with IC50 of 15 nM in in the G9a Thioglo assay.
|
A14401 |
BRD4770 |
G9a inhibitor |
BRD4770 is a novel histone methyltransferase inhibitor.
|
A13947 |
3-deazaneplanocin A HCl (DZNep HCl) |
EZH2 inhibitor |
3-deazaneplanocin A, also known as DZNep, is a well-known histone methyltransferase inhibitor, which disrupts polycomb-repressive complex 2 (PRC2), and induces apoptosis, while inhibiting proliferation and metastasis, in cancer cells, including acute myeloid leukemia, breast cancer and glioblastoma.
|
A14320 SALE |
UNC0379 |
SETD8 HMTase inhibitor |
UNC0379 is a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8. Its affinity to SETD8 was confirmed by ITC (isothermal titration calorimetry) and SPR (surface plasmon resonance) studies.
|
A14216 SALE |
PFI-2 |
SETD7 inhibitor |
PFI-2 is a potent, selective, and cell-active lysine methyltransferase SETD7 inhibitor with Ki (app) and IC50 of 0.33 nM and 2 nM, 1000-fold selectivity over other methyltransferases and other non-epigenetic targets.
|
A14218 |
MI-3 |
menin-MLL interaction inhibitor |
MI-3 is a potent menin-MLL interaction inhibitor with IC50 of 648 nM.
|
A13690 SALE |
UNC 0638 |
G9a/GLP inhibitor |
UNC 0638 is a selective inhibitor of G9a and GLP histone lysine methyltransferases.
|
A13876 |
C7280948 |
PRMT1 inhibitor |
C7280948 is an inhibitor of histone arginine methyltransferase PRMT1 with IC50 values of 12.75 uM.
|
A12439 |
EPZ005687 |
EZH2 inhibitor |
EPZ005687 is a potent inhibitor of EZH2 (K(i) of 24 nM)
|
A16405 |
Amodiaquine dihydrochloride dihydrate |
- |
Amodiaquine is a potent, non-competitive inhibitor of histamine N-methyl transferase in human erythrocytes, also used as an antimalarial and anti-inflammatory agent.
|
50 Item(s)
per page
FILTER BY:
Shopping Options
- Target
- Actions
-
- Antagonist (2)
- Inhibitor (46)
Adooq Guarantee
Guaranteed product quality
We promise all products perform as described.
